We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+44.2%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.62B
AUM Growth
+$469M
Cap. Flow
-$157M
Cap. Flow %
-5.99%
Top 10 Hldgs %
40.11%
Holding
87
New
14
Increased
8
Reduced
51
Closed
6

Top Buys

Rank Stock Value
1
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$147M
2
RNAM
Avidity Biosciences
RNAM
+$72.5M
3
ARCT icon
Arcturus Therapeutics
ARCT
+$18.5M
4
PLRX icon
Pliant Therapeutics
PLRX
+$16.2M
5
QURE icon
uniQure
QURE
+$11.5M

Top Sells

Rank Stock Value
1
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$64.1M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$33.9M
3
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$31.5M
4
XLRN
Acceleron Pharma
XLRN
+$21.7M
5
IMVTU
Immunovant, Inc. Units
IMVTU
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 81.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TPTX
1
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$177M 6.75%
2,737,297
-319,500
-10% -$18.4M
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$154M 5.88%
500,000
-500,000
-50% -$146M
FMTX
3
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$153M 5.82%
+3,379,373
New +$147M
CCXI
4
DELISTED
ChemoCentryx, Inc.
CCXI
$97.8M 3.73%
1,700,000
-325,000
-16% -$17.7M
PRNB
5
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$95.1M 3.63%
1,590,493
-509,507
-24% -$31.5M
BBIO icon
6
BridgeBio Pharma
BBIO
$16.4B
$84.5M 3.22%
2,590,762
-359,238
-12% -$10.9M
RVMD icon
7
Revolution Medicines
RVMD
$38.5B
$82.7M 3.16%
2,636,661
-130,417
-5% -$4.1M
IWM icon
8
PUT
iShares Russell 2000 ETF
IWM
$79.1B
$71.6M 2.73%
+500,000
New +$65.6M
YMAB
9
DELISTED
Y-mAbs Therapeutics
YMAB
$68M 2.6%
1,574,683
-157,517
-9% -$5.96M
RNAM
10
DELISTED
Avidity Biosciences
RNAM
$67.8M 2.59%
+2,514,547
New +$72.5M
APLS
11
DELISTED
Apellis Pharmaceuticals
APLS
$67.5M 2.57%
2,066,108
-200,000
-9% -$6.42M
VIE
12
DELISTED
Viela Bio, Inc. Common Stock
VIE
$65.5M 2.5%
1,512,500
-250,000
-14% -$11.3M
RETA
13
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$62.4M 2.38%
400,000
-87,206
-18% -$13.3M
MYOK
14
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$58M 2.21%
600,000
-100,000
-14% -$8.34M
CCXI
15
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
$57.5M 2.2%
1,000,000
+375,000
+60% +$20.4M
XLRN
16
DELISTED
Acceleron Pharma
XLRN
$57.2M 2.18%
600,000
-225,000
-27% -$21.7M
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$57.1M 2.18%
500,000
-350,000
-41% -$33.9M
XBI icon
18
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
$56M 2.14%
+500,000
New +$49.2M
MYOV
19
DELISTED
Myovant Sciences Ltd.
MYOV
$51.5M 1.97%
2,500,000
-100,000
-4% -$1.36M
EIDX
20
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$50.3M 1.92%
1,055,302
-44,698
-4% -$2.08M
BHVN
21
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$43.9M 1.67%
600,000
-275,551
-31% -$14.7M
AGEN
22
Agenus
AGEN
$276M
$43.2M 1.65%
560,450
-59,840
-10% -$3.58M
OMER icon
23
Omeros
OMER
$845M
$40.8M 1.56%
2,775,000
+251,300
+10% +$3.75M
SRNE
24
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$40.8M 1.56%
6,500,000
+1,500,000
+30% +$5.74M
STOK icon
25
Stoke Therapeutics
STOK
$1.84B
$40.5M 1.55%
1,701,292
-8,473
-0.5% -$201K
1
2 3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q2 2020 Portfolio in Review

As of Q2 2020, Cormorant Asset Management held 87 positions worth $2.62B, up 22% from $2.15B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Cormorant Asset Management withdrew a net $157M in Q2 2020, closing 6 positions and reducing 51 holdings. Its most notable exit was Constellation Pharmaceuticals, Inc., an estimated $64.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 76% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in Forma Therapeutics Holdings, Inc. Common Stock worth $153M.

  • Cormorant Asset Management's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 3,379,373 shares worth $153M.
  • Cormorant Asset Management added most to Arcturus Therapeutics in Q2 2020, an estimated $18.5M increase.
  • Cormorant Asset Management's biggest Q2 2020 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $33.9M.
  • Cormorant Asset Management fully exited Constellation Pharmaceuticals, Inc. in Q2 2020, selling an estimated $64.1M.
  • Cormorant Asset Management's ten largest holdings make up 40% of its $2.62B portfolio in Q2 2020.
  • Cormorant Asset Management opened 14 new positions and closed 6 in Q2 2020.
  • Cormorant Asset Management's portfolio value rose 22% quarter-over-quarter to $2.62B.

Based on Cormorant Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.